THE DIFFERENTIATED CARCINOMA OF FOLLICULAR STRAIN OF THYROID:

ABOUT FAMILY CASES

LYNDA BELABAS, NABILA MEZIANI,FELLA HABELLAOUI,OUIDAD BAZ, SAFIA MIMOUNI ZERGUINI

ENDOCRINOLOGY UNIT PIERRE AND MARIE CURIE CENTER, ALGIERS, ALGERIA

Introduction Objectives
Thyroid cancer (TC) is the most common endocrine malignancy To evaluate the degree of
with an increased incidence rate. Papillary thyroid carcinoma aggressiveness of FPTC by
(PTC) constitutes 80% of all (TC) and 5-15% of these cases are describing the
considered familial, called familial papillary thyroid carcinoma epidemiological, clinical,
(FPTC), which have been proposed as an aggressive clinical anatomo-pathological and
entity. A specific genetic defect responsible for this disease and evolutionary characteristics.
its inheritance has not yet been established

Methods
Descriptive and retrospective study of 13 families, with a total of 27 patients with FPTC, supported in
the Endocrinology Department at CPMC from January 2004 to January 2018.
The parameters taken into account are: anamnestic, clinical, para-clinical and response data after
ira-therapy.

Results
We collected 27 patients with a mean age of Clinical Curse
46 years with a history of familial goiters in 65% of
cases.
First degree relatives are found in 74%.
Ablative surgery type: total thyroidectomy in 85%
of cases, and lymph node dissection in 55% of
cases. lymph node
A pure papillary TC is found in 74% of cases and a 26% metastasis
histological variant in 19% of cases;capsular 57% remote
effraction in 52% of cases and multifocality in 41% metastasis
of cases; 17% good evolution
The evolution was marked by the appearance of :
06 cases of lymph nodes metastases and 04 cases
of distant metastases.
13 patients evolved favorably.

Conclusions
Despite the presence of adverse histopathological prognostic features, surgical and isotopic
treatment has been shown to be curative in most patients with FNMTC, who show good
progression, without evidence of a high rate of metastases, with overall survival of patients not
seeming to be affected.
References
1)L. Leenhardt a, P. Grosclaude Service de médecine nucléaire, hôpital Pitié-Salpêtrière, Université Paris-VI, 47– 83, boulevard de
l’hôpital, 75651 Paris cedex 13, France
2) Willieford Moses,1 Julie Weng,1 and Electron Kebebew2
3) Thomas J.McDonald,1 Albert A. Driedger,2 Bertha M. Garcia,3Stanislaus H. M. Van Uum,1 Irina Rachinsky,2 Vijaya Chevendra,1
Daniel Breadner,1Richard Feinn,4 Stephen J.Walsh,
4) Anto´ nio E Pinto1, Giovani L Silva4,5, Rui Henrique6,8, Francisco D Menezes6,Manuel R Teixeira7,8, Valeriano Leite2,3,9 and
Branca M Cavaco2,9